Key result
Statin plus evolocumab linked to ~65% lower unstable angina rehospitalization risk in STEMI with NIRA.
Why the study?
The effects of combining evolocumab and statin on clinical outcomes and coronary artery physiological function in STEMI patients with non-infarct-related artery disease are unclear.
Does statin plus evolocumab improve coronary artery physiological function and reduce rehospitalization for unstable angina in STEMI patients with non-infarct-related artery disease compared to statin monotherapy?
Cohort (n=355)
Does statin plus evolocumab improve coronary artery physiological function and reduce rehospitalization for unstable angina in STEMI patients with non-infarct-related artery disease compared to statin monotherapy?
Adding evolocumab to statin therapy in STEMI patients with non-infarct-related artery disease improves coronary physiology and reduces rehospitalization for unstable angina at 12 months.
Answers are grounded in this paper and cite their sources.
Evolocumab plus statin may improve NIRA metrics in STEMI; leaves open clinical benefits and requires randomized confirmation.
Purpose: The effects of combing evolocumab and statin on the clinical outcome and physiological function of coronary arteries in STEMI patients with non-infarct-related artery (NIRA) disease are still unclear. Methods: A total of 355 STEMI patients with NIRA were enrolled in this study, who underwent combined quantitative flow ratio (QFR) at baseline and after 12 months of treatment with statin monotherapy or statin plus evolocumab. Results: Diameter stenosis and lesion length were significantly lower in the group undergoing statin plus evolocumab. While the group exhibited significantly higher minimum lumen diameter (MLD), and QFR values. Statin plus evolocumab (OR = 0.350; 95% CI: 0.149-0.824; P = 0.016) and plaque lesion length (OR = 1.223; 95% CI: 1.102-1.457; P = 0.033) were independently associated with rehospitalization for unstable angina (UA) within 12 months. Conclusion: Evolocumab combined with statin therapy can significantly improve the anatomical and physiological function of the coronary arteries and downregulate the re-hospitalization rate due to UA in STEMI patients with NIRA.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a cohort in ST-Elevation Myocardial Infarction (STEMI) with non-infarct-related artery (NIRA) disease (n=355). Statin plus evolocumab vs. Statin monotherapy was evaluated on Rehospitalization for unstable angina (UA) within 12 months (OR 0.350, 95% CI 0.149-0.824, p=0.016). Statin plus evolocumab was associated with a lower risk of rehospitalization for unstable angina within 12 months in STEMI patients with NIRA.
Synapse has enriched 10 related papers. Consider them for comparative context: